121 related articles for article (PubMed ID: 37945310)
1. Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic factors and survival outcomes.
Dong S; Zhong A; Zhu H; Wang K; Cheng CS; Meng Z
Int J Hyperthermia; 2023; 40(1):2278417. PubMed ID: 37945310
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
3. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer.
Ning ZY; Cheng CS; Xie J; Chen QW; Xu LT; Zhuang LP; Zhang CY; Song LB; Shi WD; Zhu XY; Wang P; Wang K; Meng ZQ
Discov Med; 2016 Jun; 21(118):435-45. PubMed ID: 27448780
[TBL] [Abstract][Full Text] [Related]
4. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system.
Yang C; Cheng H; Luo G; Lu Y; Guo M; Jin K; Wang Z; Yu X; Liu C
Eur J Surg Oncol; 2017 Nov; 43(11):2112-2118. PubMed ID: 28802662
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
Cetin S; Dede I
J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
[TBL] [Abstract][Full Text] [Related]
8. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
9. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
[No Abstract] [Full Text] [Related]
10. [Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].
Wu LL; Cai MZ; Wang BG; Deng JY; Ke B; Zhang RP; Liang H; Wang XN
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):680-688. PubMed ID: 37583026
[No Abstract] [Full Text] [Related]
11. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
[TBL] [Abstract][Full Text] [Related]
12. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.
Huang Q; Diao P; Li CL; Peng Q; Xie T; Tan Y; Lang JY
Medicine (Baltimore); 2020 Jan; 99(4):e18607. PubMed ID: 31977852
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer.
Zhao J; Zhao F; Shi Y; Deng Y; Hu X; Shen H
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2105-2111. PubMed ID: 28620685
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
Qi Q; Geng Y; Sun M; Wang P; Chen Z
Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
[TBL] [Abstract][Full Text] [Related]
17. Can Albumin Bilirubin Ratio and Inflammatory Prognostic Index Be A New Marker Determining Survival in Metastatic Pancreatic Cancer?
Ekinci F; Sarı D; Çelik C; Dirican A; Erdoğan AP; Gökse G
Gulf J Oncolog; 2021 May; 1(36):45-52. PubMed ID: 35017135
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer.
Iwai N; Okuda T; Sakagami J; Harada T; Ohara T; Taniguchi M; Sakai H; Oka K; Hara T; Tsuji T; Komaki T; Kagawa K; Yasuda H; Naito Y; Itoh Y
Sci Rep; 2020 Oct; 10(1):18758. PubMed ID: 33127996
[TBL] [Abstract][Full Text] [Related]
19. High Intensity Focused Ultrasound Ablation for Patients With Locally Advanced Pancreatic Adenocarcinoma: A Propensity Score-Matching Analysis.
Ning J; Wang S; Guo Y; Diao J; Bai X; Wang H; Hu K; Zhao Q
J Ultrasound Med; 2023 Jul; 42(7):1595-1607. PubMed ID: 36691925
[TBL] [Abstract][Full Text] [Related]
20. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
